Solid Tumor Testing Market Size, Share, Growth, and Industry Analysis, By Type (Conventional testing,Non-conventional testing), By Application (Hospitals,Diagnostic laboratories,Academic and research institutes), Regional Insights and Forecast to 2035

Solid Tumor Testing Market Overview

The global Solid Tumor Testing Market size is projected to grow from USD 29312.11 million in 2026 to USD 31284.82 million in 2027, reaching USD 52696.44 million by 2035, expanding at a CAGR of 6.73% during the forecast period.

The Solid Tumor Testing Market includes molecular diagnostics, biomarker assays, genomic profiling, imaging + pathology integration used for diagnosing, monitoring, and guiding therapy in solid cancers. In 2023, global solid tumor testing demand was valued at approximately USD 20.5 billion across assays in lung, breast, colorectal, melanoma, and other tumor types.

In the USA market, solid tumor testing is dominant, with U.S. test volume exceeding 7,700 million USD in 2023, representing about 40 % of the global market. The U.S. has more than 2,500 molecular pathology labs and deploys over 1,200 FDA-cleared biomarker assays.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 62 % of global cancer diagnostics incorporate genetic profiling
• Major Market Restraint: 28 % of healthcare systems cite reimbursement restrictions
• Emerging Trends: 35 % of new assays integrate liquid biopsy modules
• Regional Leadership: North America holds about 40 % of total market value
• Competitive Landscape: Top 5 players command 55 % market share
• Market Segmentation: Genetic testing accounts for 65 % of all solid tumor assays
• Recent Development: 22 % increase in multiplex panel launches in 2024

Solid Tumor Testing Market Latest Trends

In recent years, a primary trend in the Solid Tumor Testing Market is the shift toward multi-gene panels and multiplex assays: by 2024, about 65 % of assays offered tested 50+ genes rather than single biomarkers. This enables simultaneous detection of EGFR, ALK, BRAF, and other mutations in lung or colorectal cancer.

Solid Tumor Testing Market Dynamics

The Solid Tumor Testing Market Dynamics are shaped by the global increase in cancer prevalence, diagnostic innovation, and adoption of molecular profiling. Over 19 million new solid tumor cases are diagnosed annually, fueling the need for advanced testing. Molecular assays now represent 65 % of all tumor diagnostics, driven by rising demand for targeted therapy guidance.

DRIVER

"Rising cancer incidence and precision oncology adoption."

Cancer incidence globally is rising: in 2020, about 19.3 million new cancer cases were recorded, of which 70 % were solid tumors such as lung, breast, colorectal, prostate, and melanoma. As treatment shifts toward targeted therapies, oncologists increasingly rely on tumor genetic profiling.

RESTRAINT

"Reimbursement challenges and cost constraints."

One major restraint in the solid tumor testing market is variable reimbursement and cost pressure. In many markets, insurers cover only a limited subset of molecular panels about 28 % of advanced tests face coverage denial.

OPPORTUNITY

"Expansion in emerging markets, liquid biopsy, and multiplex innovation."

Significant opportunity lies in expansion in Asia, Latin America, and Africa, where molecular testing penetration remains under 15 % of cancer patients. Many emerging markets have rising cancer burdens: China expects 4 million new cancer cases in 2025. Introducing affordable, localized tumor testing workflows can unlock large volumes.

CHALLENGE

"Complexity of variant interpretation, regulatory barriers, and data management."

A key challenge in the solid tumor testing market is variant interpretation complexity. Many detected variants are “variants of unknown significance” (VUS) in panels, 25–30 % of variants fall in that category. Harmonizing variant annotation across labs is difficult; inter-lab discrepancy rates of 12 % are reported in ring trials.

Solid Tumor Testing Market Segmentation

The Solid Tumor Testing Market is segmented by type (Conventional testing, Non-conventional testing) and by application (Hospitals, Diagnostic laboratories, Academic & research institutes). Type segmentation reflects whether assays rely on classical pathology/immunohistochemistry or advanced molecular methods. Application segmentation tracks where testing occurs hospital molecular lab, reference diagnostic center, or academic R&D.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Conventional Testing: Conventional testing includes histopathology, immunohistochemistry (IHC), fluorescent in situ hybridization (FISH) and enzyme assays. Even in 2024, conventional tests account for about 35 % of all solid tumor diagnostic volume globally. Many lower-resource settings rely heavily on IHC for markers such as HER2, ER/PR, and PD-L1. Over 4,000 hospitals globally perform IHC on biopsy sections prior to molecular referral.

The Conventional Testing Segment in the Solid Tumor Testing Market is valued at approximately USD 12,570.0 million in 2025, projected to reach USD 22,606.0 million by 2034, accounting for 45.8 % of the global market share and registering a CAGR of 6.73 % throughout the forecast period.

Top 5 Major Dominant Countries in the Conventional Testing Segment

• United States: The United States Conventional Testing Market is projected to increase from USD 5,700.0 million in 2025 to USD 10,260.0 million by 2034, recording a CAGR of 6.73 % and accounting for approximately 45.4 % of the global conventional testing segment. The U.S. leads due to its extensive network of over 1,800 pathology laboratories performing more than 12 million IHC and FISH assays annually. Approximately 80 % of cancer centers conduct conventional testing before molecular sequencing, while automation adoption across leading labs has grown by 25 % since 2020. These dynamics sustain the country’s dominant share within the Solid Tumor Testing Market Forecast.
• Germany: The Germany Conventional Testing Market expands from USD 1,200.0 million in 2025 to USD 2,160.0 million by 2034, registering a CAGR of 6.73 % and holding around 9.6 % of the total segment share. Germany’s strong growth is supported by more than 500 specialized pathology laboratories conducting high-volume IHC and FISH tests, with over 70 % using automated slide staining and digital imaging systems. National oncology regulations mandate the use of conventional assays in tumor grading and biomarker screening, ensuring consistent diagnostic utilization throughout German cancer networks and research centers.
• United Kingdom: The United Kingdom Conventional Testing Market rises from USD 1,000.0 million in 2025 to USD 1,800.0 million by 2034, maintaining a CAGR of 6.73 % and securing approximately 8.0 % of the global share. The U.K. market benefits from the structured operations of the National Health Service (NHS), where over 400 accredited diagnostic facilities perform more than 2.5 million histopathology slide analyses annually. Adoption of artificial intelligence-assisted pathology has reached 30 % across NHS oncology centers, optimizing diagnostic accuracy and reducing turnaround times by 20 %, thereby reinforcing growth within the Solid Tumor Testing Industry Report framework.
• Japan: The Japan Conventional Testing Market increases from USD 900.0 million in 2025 to USD 1,620.0 million by 2034, registering a CAGR of 6.73 % and capturing about 7.2 % of the global conventional testing segment. Japan maintains a robust diagnostic infrastructure, with more than 350 hospital laboratories performing routine IHC and histopathological evaluations for solid tumors annually. Approximately 78 % of cancer patients undergo tissue-based testing prior to molecular profiling. The Ministry of Health’s promotion of digital pathology standardization has driven the adoption of automated slide scanners in 60 % of laboratories, enhancing both throughput and data quality in diagnostic operations.
• China: The China Conventional Testing Market grows from USD 1,100.0 million in 2025 to USD 1,980.0 million by 2034, achieving a CAGR of 6.73 % and accounting for roughly 8.8 % of the global conventional testing share. China’s rapid expansion is supported by the establishment of over 3,000 tertiary hospitals equipped with pathology units performing conventional assays for over 10 million cancer patients annually. Approximately 75 % of diagnostic workflows in public oncology institutions incorporate IHC as a primary confirmatory method before genetic testing. Strong government investments in healthcare modernization and quality control initiatives are expected to increase laboratory automation by 35 % by 2030, sustaining China’s upward trajectory in the Solid Tumor Testing Market Outlook.

Non-conventional Testing: Non-conventional molecular testing comprises next-generation sequencing (NGS), real-time PCR, multiplex PCR, digital PCR, targeted panels, RNA fusion tests and ctDNA assays. In 2024, non-conventional tests capture 65 % of solid tumor testing market value. Among these, NGS panels account for 45 % of molecular volume.

The Non-Conventional Testing Segment in the Solid Tumor Testing Market is valued at USD 14,893.8 million in 2025, rising to USD 26,767.6 million by 2034, capturing approximately 54.2 % of total market share with a steady CAGR of 6.73 % during the forecast period. This segment includes advanced diagnostic modalities such as next-generation sequencing (NGS), digital PCR, multiplex assays, and circulating tumor DNA (ctDNA) liquid biopsy testing.

Top 5 Major Dominant Countries in the Non-Conventional Testing Segment

• United States: The United States Non-Conventional Testing Market grows from USD 7,400.0 million (2025) to USD 13,300.0 million (2034), with a CAGR of 6.73 % and 49.7 % global share. The U.S. leads with 1,600 CLIA-certified molecular labs performing over 2 million NGS panels annually. Liquid biopsy adoption has exceeded 25 % of test volumes, and AI-based data processing automates 70 % of genomic variant analysis workflows, reinforcing its dominance in molecular oncology diagnostics.
• China: The China Non-Conventional Testing Market increases from USD 1,800.0 million (2025) to USD 3,240.0 million (2034), registering a CAGR of 6.73 % and 12.1 % global share. China’s National Cancer Genomics Program targets testing 1 million patients annually by 2028 using molecular platforms. Over 500 NGS labs operate nationwide, with domestic production supplying 60 % of oncology diagnostic reagents and rapidly lowering testing costs across provincial health systems.
• Germany: The Germany Non-Conventional Testing Market grows from USD 1,200.0 million (2025) to USD 2,160.0 million (2034), achieving a CAGR of 6.73 % and 8.1 % segment share. Germany hosts 400 + molecular diagnostic centers with AI-enabled PCR and NGS automation, reducing report times by 30 %. Reimbursement coverage for tumor sequencing now exceeds 80 % of eligible oncology patients under national insurance programs.
• Japan: The Japan Non-Conventional Testing Market rises from USD 1,100.0 million (2025) to USD 1,980.0 million (2034), posting a CAGR of 6.73 % and 7.4 % global share. Japan’s National Cancer Genomics Initiative has profiled 60,000 + tumor samples since 2020. About 55 % of laboratories use multiplex PCR and fusion-gene panels, and 350 + hospitals conduct routine molecular testing integrated with national cancer registries.
• South Korea: The South Korea Non-Conventional Testing Market expands from USD 800.0 million (2025) to USD 1,440.0 million (2034), maintaining a CAGR of 6.73 % and 5.4 % segment share. More than 80 molecular diagnostic labs operate under government Bio-Health initiatives, while AI-powered genomic analytics increased processing efficiency by 40 % since 2020. South Korea is emerging as Asia’s innovation hub for liquid biopsy and NGS-based solid tumor profiling.

BY APPLICATION

Hospitals: Hospitals (oncology centers) conduct the majority of solid tumor testing. In 2024, hospital labs accounted for 60 % of global molecular and conventional assay volume. Over 3,500 tertiary hospitals globally offer in-house molecular tumor testing. Hospitals integrate testing into care workflows for biopsy, surgery, and therapy monitoring. Many cancer centers perform 10,000+ tumor panels annually. Hospitals often subsidize testing or negotiate bulk pricing via insurance contracts.

The Hospitals Application Segment in the Solid Tumor Testing Market is valued at USD 13,731.9 million in 2025, projected to reach USD 24,667.8 million by 2034, capturing around 50.0 % global share and maintaining a CAGR of 6.73 % throughout the forecast period.

Top 5 Major Dominant Countries in the Hospitals Application

• United States: The United States Hospital Segment grows from USD 6,500.0 million (2025) to USD 11,680.0 million (2034), posting a CAGR of 6.73 % and holding 47.3 % share. Over 2,500 oncology hospitals in the U.S. integrate solid tumor testing, with 80 % equipped with on-site genomic laboratories, driving early diagnostic precision and therapy matching rates.
• Germany: The Germany Hospital Segment increases from USD 1,400.0 million (2025) to USD 2,520.0 million (2034), with a CAGR of 6.73 % and 10.2 % regional share. Around 400 + hospitals conduct routine tumor sequencing supported by national cancer programs promoting early detection and biomarker mapping.
• United Kingdom: The U.K. Hospital Segment grows from USD 1,200.0 million (2025) to USD 2,160.0 million (2034), maintaining a CAGR of 6.73 % and 8.7 % share. NHS oncology centers perform more than 3 million annual diagnostic tests for solid tumors, reinforcing strong institutional integration.
• China: The China Hospital Segment rises from USD 1,300.0 million (2025) to USD 2,340.0 million (2034), sustaining a CAGR of 6.73 % and 9.5 % share. China operates 3,000 + tertiary hospitals with oncology units conducting histopathology and NGS-based testing, contributing to nationwide diagnostic advancement.
• Japan: The Japan Hospital Segment advances from USD 1,000.0 million (2025) to USD 1,800.0 million (2034), achieving a CAGR of 6.73 % and 7.3 % share. Over 350 + hospitals provide integrated molecular oncology services, enhancing personalized treatment accuracy and testing throughput.

Diagnostic Laboratories: Diagnostic reference laboratories perform 30 % of solid tumor tests in 2024. These labs handle high volume external referrals, often serving multiple hospitals or regions. Many labs run 5,000–20,000 tumor panels per year. They invest in high-throughput NGS systems and robust bioinformatics pipelines. They also provide centralized services across rural areas and international sample logistics.

The Diagnostic Laboratories Segment in the Solid Tumor Testing Market is valued at USD 8,239.1 million in 2025, increasing to USD 14,803.8 million by 2034, accounting for approximately 30.0 % share globally with a CAGR of 6.73 %.

Top 5 Major Dominant Countries in the Diagnostic Laboratories Application

• United States: The U.S. Diagnostic Labs Segment expands from USD 3,800.0 million (2025) to USD 6,830.0 million (2034), showing a CAGR of 6.73 % and 46.1 % segment share. Over 1,500 certified molecular labs handle 60 % of off-site oncology testing demand.
• China: The China Diagnostic Labs Segment grows from USD 1,200.0 million (2025) to USD 2,100.0 million (2034), marking a CAGR of 6.73 % and 14.6 % share. Expansion of private diagnostic networks and domestic kit manufacturing drives local testing accessibility.
• Germany: The Germany Diagnostic Labs Segment rises from USD 900.0 million (2025) to USD 1,620.0 million (2034), maintaining a CAGR of 6.73 % and 10.9 % share. Over 300 + private and institutional labs deliver precision diagnostics to major cancer centers nationwide.
• Japan: The Japan Diagnostic Labs Segment advances from USD 700.0 million (2025) to USD 1,260.0 million (2034), achieving a CAGR of 6.73 % and 8.5 % share. Laboratories prioritize automation and AI-based tumor panel analysis to enhance diagnostic speed and accuracy.
• United Kingdom: The U.K. Diagnostic Labs Segment grows from USD 500.0 million (2025) to USD 900.0 million (2034), posting a CAGR of 6.73 % and 6.1 % share. Collaborations between NHS and private diagnostic companies expand high-throughput genomic sequencing access.

Academic & Research Institutes: Academic and research institutes execute 10 % of solid tumor testing volume, primarily for clinical trials, biomarker discovery, and assay development. In 2024, over 500 universities and cancer centers ran tumor genomic studies. Many institutes distribute tumor testing kits to trials enrolling 10,000+ patients. Their focus is innovation, validation, and translational biomarker pipelines, often supplementing clinical diagnostics in leading centers.

The Academic & Research Institutes Segment in the Solid Tumor Testing Market is estimated at USD 4,492.8 million in 2025, projected to reach USD 8,181.9 million by 2034, holding around 16.4 % global share and registering a CAGR of 6.73 %.

Top 5 Major Dominant Countries in the Academic & Research Institutes Application

• United States: The U.S. Research Segment expands from USD 1,800.0 million (2025) to USD 3,280.0 million (2034), with a CAGR of 6.73 % and 40.1 % share. Over 400 + academic centers conduct multi-omics cancer studies supported by NIH funding.
• Germany: The Germany Research Segment rises from USD 600.0 million (2025) to USD 1,100.0 million (2034), maintaining a CAGR of 6.73 % and 13.4 % share. German cancer research hubs advance diagnostic innovations through translational oncology programs.
• China: The China Research Segment increases from USD 700.0 million (2025) to USD 1,300.0 million (2034), achieving a CAGR of 6.73 % and 15.6 % share. Over 250 academic labs collaborate on molecular tumor biomarker validation initiatives.
• Japan: The Japan Research Segment grows from USD 500.0 million (2025) to USD 910.0 million (2034), posting a CAGR of 6.73 % and 11.1 % share. National genomic data-sharing programs foster rapid translational testing development.
• United Kingdom: The U.K. Research Segment advances from USD 400.0 million (2025) to USD 720.0 million (2034), with a CAGR of 6.73 % and 8.9 % share. Major research universities partner with oncology startups to commercialize precision testing platforms.

Regional Outlook for the Solid Tumor Testing Market

Regional performance in the Solid Tumor Testing Market is concentrated in North America (40 % share), followed by Europe (25 %), Asia-Pacific (25 %), and Middle East & Africa (10 %). North America leads in per-patient testing intensity, while Asia is rising fast in volume growth. Europe holds strength in regulatory harmonization and reimbursement. Middle East & Africa trail due to infrastructure gaps but present high-opportunity growth corridors.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America commands approximately 40 % of global solid tumor testing volume, driven by advanced healthcare infrastructure, reimbursement coverage, and strong R&D penetration. In 2023, North America test expenditures were about USD 7.7 billion, dominated by the United States, which contributed approximately USD 7.1 billion. Canada and Mexico account for the rest Canada running about USD 1,176.8 million worth of tumor tests. U.S. cancer incidence is rising over 1.8 million new cases reported annually thereby driving broad adoption of genomic profiling.

The North America Solid Tumor Testing Market is projected at USD 10,985.5 million in 2025, rising to USD 19,744.3 million by 2034, holding approximately 40.0 % of the global market share and maintaining a steady CAGR of 6.73 %.

North America – Major Dominant Countries in the Solid Tumor Testing Market

• United States: The United States Solid Tumor Testing Market grows from USD 9,400.0 million (2025) to USD 16,900.0 million (2034), with a CAGR of 6.73 % and 85.5 % share. Over 1,600 + molecular diagnostic labs perform over 2 million solid tumor profiles annually, ensuring continuous innovation in precision oncology.
• Canada: The Canada Solid Tumor Testing Market rises from USD 900.0 million (2025) to USD 1,620.0 million (2034), maintaining a CAGR of 6.73 % and 8.2 % share. More than 250 public diagnostic centers provide national genomic cancer testing supported by government oncology programs.
• Mexico: The Mexico Solid Tumor Testing Market increases from USD 300.0 million (2025) to USD 540.0 million (2034), posting a CAGR of 6.73 % and 2.7 % share. The country expands molecular pathology infrastructure through healthcare modernization projects.
• Puerto Rico: The Puerto Rico Solid Tumor Testing Market advances from USD 50.0 million (2025) to USD 90.0 million (2034), achieving a CAGR of 6.73 % and 0.5 % share. Hospital-based testing capacity is improving with increased adoption of tissue-based diagnostics.
• Bahamas: The Bahamas Solid Tumor Testing Market grows from USD 35.5 million (2025) to USD 64.3 million (2034), reflecting a CAGR of 6.73 % and 0.3 % share. Private healthcare facilities lead in adopting molecular tumor panels for regional oncology care.

EUROPE

Europe holds about 25 % of global solid tumor testing market share. Leading countries Germany, U.K., France, Italy, Spain together conduct 4.5–6.0 billion USD of tumor testing annually. Germany hosts over 600 molecular pathology labs; U.K.’s NHS network coordinates testing across 200+ oncology centers. European guidelines increasingly mandate biomarker testing in lung, breast, and colorectal cancers compliance levels surpass 75 % in major markets.

The Europe Solid Tumor Testing Market is estimated at USD 6,865.9 million in 2025, projected to reach USD 12,215.7 million by 2034, representing around 25.0 % of the global share and registering a CAGR of 6.73 %.

Europe – Major Dominant Countries in the Solid Tumor Testing Market

• Germany: The Germany Solid Tumor Testing Market rises from USD 1,700.0 million (2025) to USD 3,030.0 million (2034), maintaining a CAGR of 6.73 % and 24.8 % share. More than 400 labs conduct tumor genotyping supported by strong reimbursement systems.
• United Kingdom: The U.K. Solid Tumor Testing Market increases from USD 1,300.0 million (2025) to USD 2,320.0 million (2034), at a CAGR of 6.73 % and 18.9 % share. NHS Genomic Medicine Service facilitates large-scale cancer genome sequencing.
• France: The France Solid Tumor Testing Market grows from USD 1,100.0 million (2025) to USD 1,960.0 million (2034), showing a CAGR of 6.73 % and 16.0 % share. Over 150 oncology centers perform integrated molecular testing for tumor subtyping.
• Italy: The Italy Solid Tumor Testing Market advances from USD 900.0 million (2025) to USD 1,610.0 million (2034), with a CAGR of 6.73 % and 13.1 % share. Regional laboratories collaborate under national cancer genomics programs for biomarker discovery.
• Spain: The Spain Solid Tumor Testing Market grows from USD 865.9 million (2025) to USD 1,550.0 million (2034), achieving a CAGR of 6.73 % and 12.6 % share. Public hospitals expand NGS testing capacity through EU-supported oncology projects.

ASIA-PACIFIC

Asia-Pacific accounts for about 25 % of global solid tumor testing market volume. Growth is fastest in China, India, Japan, South Korea, and ASEAN nations. China alone runs millions of tumor panels annually, backed by national precision oncology programs covering 100,000+ patients. India’s molecular adoption is rising: 15 % of cancer patients now receive NGS profiling in metropolitan centers. Japan and South Korea operate over 400 high-throughput genomic labs.

The Asia Solid Tumor Testing Market is valued at USD 6,865.9 million in 2025, expected to reach USD 12,215.7 million by 2034, holding approximately 25.0 % global share and exhibiting a CAGR of 6.73 %.

Asia – Major Dominant Countries in the Solid Tumor Testing Market

• China: The China Solid Tumor Testing Market grows from USD 2,400.0 million (2025) to USD 4,260.0 million (2034), recording a CAGR of 6.73 % and 35.0 % share. 500 + NGS laboratories drive national genomic cancer testing growth.
• Japan: The Japan Solid Tumor Testing Market rises from USD 1,500.0 million (2025) to USD 2,660.0 million (2034), maintaining a CAGR of 6.73 % and 21.8 % share. Nationwide cancer genome projects enhance diagnostic accuracy.
• India: The India Solid Tumor Testing Market expands from USD 850.0 million (2025) to USD 1,520.0 million (2034), achieving a CAGR of 6.73 % and 12.4 % share. Growth is supported by 200 + new molecular testing facilities.
• South Korea: The South Korea Solid Tumor Testing Market increases from USD 700.0 million (2025) to USD 1,250.0 million (2034), posting a CAGR of 6.73 % and 10.3 % share. Biohealth strategies prioritize solid tumor diagnostics expansion.
• Australia: The Australia Solid Tumor Testing Market advances from USD 415.9 million (2025) to USD 740.0 million (2034), marking a CAGR of 6.73 % and 6.1 % share. National cancer programs encourage genomic profiling adoption across public hospitals.

MIDDLE EAST & AFRICA

Middle East & Africa comprises roughly 10 % of global solid tumor testing volume. Key markets include Saudi Arabia, UAE, Qatar, South Africa, Egypt, and Nigeria. Advanced centers in GCC conduct 50–70 % of tests in region with state financing support. South Africa hosts 80 molecular labs serving domestic and regional demand. In Egypt and Nigeria, molecular testing penetration remains under 5 % of cancer patients, but growth is accelerating with government oncology initiatives.

The Middle East & Africa Solid Tumor Testing Market is projected at USD 1,746.5 million in 2025, increasing to USD 3,197.9 million by 2034, capturing approximately 10.0 % global share with a CAGR of 6.73 %.

Middle East & Africa – Major Dominant Countries in the Solid Tumor Testing Market

• Saudi Arabia: The Saudi Arabia Solid Tumor Testing Market rises from USD 550.0 million (2025) to USD 1,010.0 million (2034), achieving a CAGR of 6.73 % and 31.5 % share. National cancer programs mandate advanced tumor diagnostics adoption.
• United Arab Emirates: The UAE Solid Tumor Testing Market increases from USD 400.0 million (2025) to USD 730.0 million (2034), at a CAGR of 6.73 % and 22.9 % share. The country’s healthcare innovation strategy drives oncology laboratory growth.
• South Africa: The South Africa Solid Tumor Testing Market grows from USD 300.0 million (2025) to USD 550.0 million (2034), with a CAGR of 6.73 % and 17.2 % share. Expansion of molecular diagnostics in urban hospitals fuels testing volumes.
• Egypt: The Egypt Solid Tumor Testing Market advances from USD 250.0 million (2025) to USD 460.0 million (2034), maintaining a CAGR of 6.73 % and 14.3 % share. Increased cancer screening programs and medical partnerships boost market accessibility.
• Nigeria: The Nigeria Solid Tumor Testing Market rises from USD 173.0 million (2025) to USD 318.0 million (2034), posting a CAGR of 6.73 % and 9.9 % share. Healthcare infrastructure development and import-based testing expansion drive future opportunities.

List of Top Solid Tumor Testing Companies

• Inviate Corporation
• Invivoscribe, Inc.
• OmniSeq
• Abbott Laboratories
• Illumina, Inc.
• Hoffmann-La Roche Ltd.
• Bio-Rad Laboratories, Inc.
• QIAGEN N.V.
• ASURAGEN, INC.
• Opko Health
• Laboratory Corporation of America Holdings
• NeoGenomics Laboratories, Inc.
• Beijing Genomics Institute (BGI)
• Guardant Health

Hoffmann-La Roche Ltd.: Holds 18 % global market share, offering over 120 oncology diagnostic assays integrated with precision therapy development platforms.

Illumina, Inc.: Commands 14 % market share, powering 70 % of global next-generation sequencing workflows for solid tumor profiling and genomic data interpretation.

Investment Analysis and Opportunities

Investment in the Solid Tumor Testing Market is robust and expanding across instruments, assays, data analytics, and decentralized testing platforms. In 2023–2025, over 100 diagnostics and molecular startups raised funding rounds totaling USD 500+ million globally, especially in Asia and North America. Capital is particularly flowing into liquid biopsy, ultra-low input NGS, AI-driven variant interpretation, and decentralized molecular labs.

New Product Development

Innovation in the Solid Tumor Testing Market continues at pace, with new assays combining sensitivity, multiplexing, and integration with patient workflows. In 2024, a molecular diagnostics firm launched a 100-gene NGS panel capable of full tumor profiling from 10 ng of DNA input a 40 % lower requirement than older panels. Also that year, a diagnostic company introduced a liquid biopsy + tissue reflex assay, returning results within 48 hours for both plasma and tumor tissue from a single workflow.

Five Recent Developments

• In 2023, Roche launched the VENTANA MMR RxDx Panel for solid tumor mismatch repair testing in colorectal cancer.
• In 2024, Guardant Health expanded its liquid biopsy panel to include 25 new cancer gene targets across gastrointestinal and lung tumors.
• In 2024, Illumina introduced a mid-throughput tumor sequencing system enabling hospitals to run 500 panels/month on-site.
• In 2025, NeoGenomics deployed a pan-cancer RNA fusion + DNA assay across 50 oncology centers, covering 30 tumor types.
• In 2025, a startup launched a portable intraoperative tumor margin sequencer tested in 3 cancer centers, with 100 surgical samples processed.

Report Coverage of Solid Tumor Testing Market

The Solid Tumor Testing Market Report offers in-depth coverage of industry metrics, segmentation, competitive analysis, and future outlook tailored for B2B stakeholders. It encompasses Solid Tumor Testing Market Analysis, Solid Tumor Testing Market Trends, Solid Tumor Testing Market Forecast, Solid Tumor Testing Market Size, Solid Tumor Testing Market Share, Solid Tumor Testing Market Growth, Solid Tumor Testing Market Outlook, Solid Tumor Testing Market Insights, and Solid Tumor Testing Market Opportunities.

Solid Tumor Testing Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 29312.11 Million in 2026
Market Size Value By	USD 52696.44 Million by 2035
Growth Rate	CAGR of 6.73% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Conventional testing Non-conventional testing By Application : Hospitals Diagnostic laboratories Academic and research institutes
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample